Targeted therapy plus chemotherapy may pack 1-2 punch against melanoma

By targeting and disabling a protein frequently found in melanoma tumors, doctors may be able to make the cancer more vulnerable to chemotherapy, according to a new study by researchers in the Duke Comprehensive Cancer Center.

“We tested a compound that can weaken the tumor by targeting a protein expressed on the surface of a melanoma cell. When chemotherapy was applied to the tumor in this weakened state it was much more effective compared to conventional therapy alone,” said Douglas Tyler, M.D., a surgeon at Duke and the Durham Veterans Affairs Medical Center, and senior investigator on this study. “These results are extremely significant because they may help us better treat patients with this deadly condition.”

Although this study was done in laboratory rats, a clinical trial applying the same concept to humans has already begun at four comprehensive cancer centers nationwide, including Duke.

The researchers published their findings from the animal study in the May 15, 2008 issue of the journal Cancer Research. Funding for this study came from the United States Department of Veterans Affairs, the Duke Institute for Genome Sciences & Policy, the Duke Comprehensive Cancer Center and Adherex Technologies, the company developing the compound that was tested in combination with chemotherapy.

After being implanted with melanoma tumors, rats were given a drug known as ADH-1, which makes it difficult for cells to bind properly to one another. The animals were then given one of two types of common chemotherapy drugs, melphalan and temozolomide.

“We found that the response to ADH-1 in combination with melphalan was more dramatic than the response to the drug in combination with temozolomide," Tyler said. "The reason may be that the melphalan was infused directly into the affected area while temozolomide is given systemically.”

The researchers saw a 30-fold reduction in tumor size following treatment with ADH-1 and melphalan chemotherapy compared to chemotherapy alone. Tumor size shrunk about twofold in response to ADH-1 and temozolomide, Tyler said.

“We saw a complete regression of the tumors in the animal model when we used the regional melphalan chemotherapy in combination with ADH-1, which is far better than anything we have seen before with the chemotherapy alone,” Tyler said. “Furthermore, the addition of ADH-1 produced no additional side effects, which is an important consideration in cancer treatment.”

Regional infusion of chemotherapy for melanoma is given under surgical conditions, through the artery and vein in the affected limbs. Melanoma often affects people on their extremities, with a common scenario being a mole that appears on the foot and then spreads up the leg.

“These results clearly demonstrate the effectiveness of combination therapies,” said Christina Augustine, Ph.D., a researcher in Duke’s Department of Surgery and lead investigator on the study. “Used alone the ADH-1 really didn’t confer any significant benefit but in combination with the melphalan chemotherapy, we saw a powerful one-two-punch effect.”

The incidence of malignant melanoma is increasing at a rate faster than any other cancer, with 60,000 new cases expected to be diagnosed this year in the United States. Melanoma that has spread beyond the primary site is rarely curable, and treatment options are limited; even when it is treated, the response rates are typically poor and most people die within six to nine months.

Source: Duke University

Related stories:

On the trail of a targeted therapy for blood cancers
Investigators from the Herman B Wells Center for Pediatric Research at the Indiana University School of Medicine are focusing on a family of blood proteins that they hope holds a key to decreasing the toxic effects of chemotherapy in children and adults.
Sensitive nanowire disease detectors made by Yale scientists
Yale scientists have created nanowire sensors coupled with simple microprocessor electronics that are both sensitive and specific enough to be used for point-of-care (POC) disease detection, according to a report in Nano Letters.
Researchers study prevention of blood clots in cancer patients
As more individuals with cancer are being treated as outpatients, the University of Rochester Medical Center is working on an emerging problem: how to prevent the life-threatening blood clots that can accompany some newer cancer drugs.
Bisphenol A linked to chemotherapy resistance
Exposure to bisphenol A (BPA) may reduce the effectiveness of chemotherapy treatments, say University of Cincinnati (UC) scientists.
Overweight men face higher risk of dying of prostate cancer
(PhysOrg.com) -- Prostate cancer patients who are overweight and have elevated insulin levels are much more likely to die of the cancer than other patients, say researchers at Harvard University and McGill University. Their research is published in the October issue of The Lancet Oncology.
Mayo researchers explore issues related to multiple myeloma treatment
Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. Unfortunately, some of the most effective therapies also have toxic side effects that can pose serious health risks and reduce quality of life. In the October issue of Mayo Clinic Proceedings, two articles authored by Mayo researchers address the issue of how to balance the risks and benefits associated with MM treatments.
New therapeutic treatment approach improves survival in esophageal cancer patients
A study released at the 73rd Annual Scientific Meeting of the American College of Gastroenterology in Orlando found that a new therapeutic treatment, when delivered endoscopically and used in combination with chemotherapy and radiation therapy, improved survival rates in patients with locally advanced esophageal cancer. Cancer of the esophagus often has a poor survival rate.
Pediatric study finds alternatives for radiation of low-grade brain tumors
A multi-institutional study led by researchers at The University of Texas M. D. Anderson Cancer Center has found that using chemotherapy alone and delaying or avoiding cranial radiation altogether can be effective in treating pediatric patients with unresectable or progressive low-grade glioma. The study was presented Sunday at the 40th annual International Society of Pediatric Oncology Meeting in Berlin, Germany.

News discussion:

Medicine & Health news